Nxstage Medical Inc (NXTM) 22.09 $NXTM
Technical Roundup on Medical Appliances and Equipment Stocks -- ZELTIQ Aesthetics, Align Technology, Nxstage Medical, and Nevro
PR Newswire - Mon Aug 01, 7:15AM CDT
One of the U.S. Healthcare sector's biggest segments, the Medical Appliances and Equipment is expected to face challenges due to stiff competition and economic uncertainties. However, constant need and demand for medical instruments should continue to drive industry growth, and the segment is anticipated to grow at a CAGR rate of about 6% through 2017, according to Espicom's 2014 report. Stock-Callers.com looks closely at the following stocks today: ZELTIQ Aesthetics Inc. (NASDAQ: ZLTQ), Align Technology Inc. (NASDAQ: ALGN), Nxstage Medical Inc. (NASDAQ: NXTM), and Nevro Corp. (NYSE: NVRO). Sign up today and download for free the research reports for the stocks covered today at:
NXTM: 22.09 (-0.02), ZLTQ: 33.57 (-0.38), ALGN: 89.69 (+0.54), NVRO: 82.34 (-0.36)
Bet on These 5 Profitable Stocks to Boost Your Returns
Zacks Equity Research - Zacks Investment Research - Mon Jul 18, 8:17AM CDT
One of the best tools to measure the future performance of a company's stocks is profitability analysis.
NXTM: 22.09 (-0.02), ALGN: 89.69 (+0.54), AL: 28.58 (-0.23), REI: 7.59 (-0.35), TAHO: 15.70 (+0.14)
Illumina (ILMN) Rallies on Exact Sciences Buyout Rumor
Zacks Equity Research - Zacks Investment Research - Wed Jul 13, 7:53AM CDT
With this buyout, Illumina (ILMN) will gain control over Cologuard -- a FDA approved non-invasive screening test of Exact Sciences that uses stool DNA technology to detect colorectal cancer.
NXTM: 22.09 (-0.02), GWPH: 96.11 (+1.79), TGTX: 5.79 (-0.12), ILMN: 170.65 (+4.30)
Boston Scientific's Restructuring Plan & Innovation Offer Hope
Zacks Equity Research - Zacks Investment Research - Wed Jul 13, 7:30AM CDT
On Jul 13, 2016, we issued an updated research report on Boston Scientific Corporation (BSX).
BSX: 24.43 (+0.15), NXTM: 22.09 (-0.02), GWPH: 96.11 (+1.79), NUVA: 63.29 (+1.09)
FDA Okays Medtronic's NuVent for Expanded Use in Sinusitis
Zacks Equity Research - Zacks Investment Research - Tue Jul 12, 7:17PM CDT
Medtronic's (MDT) NuVent is a unique balloon sinus dilation system, which enables a better view of one's sinus anatomy and the optimal placement of balloons during surgery.
NXTM: 22.09 (-0.02), MDT: 88.06 (+0.43), GWPH: 96.11 (+1.79), TGTX: 5.79 (-0.12)
Illumina Stock Hit by Downbeat Guidance, Stiff Competition
Zacks Equity Research - Zacks Investment Research - Fri Jul 08, 9:27AM CDT
Illumina (ILMN) faces high expenses related to the development of new products, their launch in various markets and investments in partnerships
ICUI: 117.07 (+0.31), NXTM: 22.09 (-0.02), GWPH: 96.11 (+1.79), ILMN: 170.65 (+4.30)
Halyard Health Now a Strong Buy, Portfolio Key Catalyst
Zacks Equity Research - Zacks Investment Research - Fri Jul 08, 7:54AM CDT
On Jul 8, 2016, Zacks Investment Research upgraded Halyard Health Inc (HYH) to a Zacks Rank #1 (Strong Buy).
HYH: 34.07 (-0.52), DSCI: 4.74 (-0.03), ICUI: 117.07 (+0.31), NXTM: 22.09 (-0.02)
Why Investors Love These Medical Appliances & Equipment's Stocks? - Align Technology, ZELTIQ Aesthetics, Amedica, and Nxstage Medical
PR Newswire - Wed Jun 22, 6:45AM CDT
Growth is expected for the U.S. Medical Appliances and Equipment industry as demand for healthcare continues to rise. In today's pre-market research, Stock-Callers.com shifts its attention on these four equities for investors' close review: Align Technology Inc. (NASDAQ: ALGN), ZELTIQ Aesthetics Inc. (NASDAQ: ZLTQ), Amedica Corp. (NASDAQ: AMDA), and Nxstage Medical Inc. (NASDAQ: NXTM). Learn more about these stocks and receive your complimentary trade alerts at:
NXTM: 22.09 (-0.02), ZLTQ: 33.57 (-0.38), ALGN: 89.69 (+0.54), AMDA: 0.84 (+0.01)
Uptrend Call Working As NxStage Medical Stock Rises 33.4% (NXTM)
Comtex SmarTrend(R) - Fri Jun 10, 1:01PM CDT
SmarTrend identified an Uptrend for NxStage Medical (NASDAQ:NXTM) on March 7th, 2016 at $15.61. In approximately 3 months, NxStage Medical has returned 33.38% as of today's recent price of $20.82.
NXTM: 22.09 (-0.02)
Nxstage Medical (NXTM) Catches Eye: Stock Jumps 5.6%
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 7:40AM CDT
Nxstage Medical, Inc. (NXTM) saw its shares almost 6% in the last trading session.
NXTM: 22.09 (-0.02), BAX: 48.50 (+0.48)
Uptrend Call Working As NxStage Medical Stock Rises 25.8% (NXTM)
Comtex SmarTrend(R) - Fri Jun 03, 1:20AM CDT
SmarTrend identified an Uptrend for NxStage Medical (NASDAQ:NXTM) on March 7th, 2016 at $15.61. In approximately 3 months, NxStage Medical has returned 25.82% as of today's recent price of $19.64.
NXTM: 22.09 (-0.02)
NxStage Medical Has Returned 19.2% Since SmarTrend Recommendation (NXTM)
Comtex SmarTrend(R) - Thu May 26, 1:52PM CDT
SmarTrend identified an Uptrend for NxStage Medical (NASDAQ:NXTM) on March 7th, 2016 at $15.61. In approximately 3 months, NxStage Medical has returned 19.15% as of today's recent price of $18.60.
NXTM: 22.09 (-0.02)
NxStage Announces Second Quarter 2016 Investor Conference Schedule
PR Newswire - Tue May 24, 7:00AM CDT
NxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company focused on advancing renal care, today announced that Jeffrey H. Burbank, Chief Executive Officer, plans to participate in the following schedule of investor conferences. Where applicable, a webcast of the event will be made available at http://ir.nxstage.com/.
NXTM: 22.09 (-0.02)
NxStage Medical Cuts Its Losses as Critical Care Leads Sales Higher
Dan Caplinger, The Motley Fool - Motley Fool - Wed May 04, 10:44AM CDT
Image source: NxStage Medical. Profitability often eludes small companies seeking to expand their businesses, and for home dialysis specialist NxStage Medical , the challenge of spending money on research and development while also marketing its...
NXTM: 22.09 (-0.02)
NxStage Reports First Quarter Financial Results
PR Newswire - Wed May 04, 7:05AM CDT
NxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company focused on advancing renal care, today reported first quarter financial results above the top end of its guidance.
NXTM: 22.09 (-0.02)
NxStage to Present at the Deutsche Bank 41st Annual Health Care Conference
PR Newswire - Mon Apr 25, 7:00AM CDT
NxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company focused on advancing renal care, today announced that Jeffrey H. Burbank, Chief Executive Officer, plans to present at the Deutsche Bank 41st Annual Health Care Conference on Thursday, May 5, 2016 at 8:40 a.m. ET in Boston, MA. A webcast of the event will be made available at http://ir.nxstage.com/.
NXTM: 22.09 (-0.02)
Zerto Launches the Inaugural ZertoCON: The Next Generation Business Continuity Conference
PR Newswire - Wed Apr 13, 7:30AM CDT
Zerto, setting the standard for protection, recovery and migration of data in cloud and virtualized data centers, today announced the launch of ZertoCON, the next generation business continuity conference, taking place May 23-25, 2016 in Boston, MA. Executives, thought leaders and IT professionals from a wide range of industries and organizations - including Zerto's management and product leaders - will focus on building confidence in IT to move businesses forward.
NXTM: 22.09 (-0.02)
NxStage® to Report First Quarter 2016 Financial Results
PR Newswire - Mon Apr 11, 7:00AM CDT
NxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company focused on advancing renal care, today announced plans to release its financial results for the first quarter ended March 31, 2016, on Wednesday, May 4, 2016, before the opening of the financial markets.
NXTM: 22.09 (-0.02)
National Donate Life Month: NxStage Teams Up with Organ Donation Nonprofit MatchingDonors.com
PR Newswire - Thu Apr 07, 7:00AM CDT
Thirteen people die every day in the United States waiting for a kidney transplant, most waiting seven to nine years, according to the U.S. Department of Health and Human Services. April is National Donate Life Month and NxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company focused on advancing renal care, is joining forces with MatchingDonors.com, the nation's largest nonprofit living organ donation website that provides people with an active way to search for an altruistic live donor. The organizations are teaming up to raise awareness of treatment options and services that may help kidney patients receive a transplant.
NXTM: 22.09 (-0.02)
Why NxStage Medical, Inc. Guided Lower Today
Brian Orelli, The Motley Fool - Motley Fool - Wed Feb 10, 3:48PM CST
What: NxStage Medical is down 14% near the closing bell after releasing disappointing guidance during its fourth-quarter earnings release this morning. So what: Fourth-quarter revenue was pretty strong, up 12% year over year. NxStage Medical...
NXTM: 22.09 (-0.02)
Technical Roundup on Medical Appliances and Equipment Stocks -- ZELTIQ Aesthetics, Align Technology, Nxstage Medical, and Nevro
PR Newswire - Mon Aug 01, 7:15AM CDT
One of the U.S. Healthcare sector's biggest segments, the Medical Appliances and Equipment is expected to face challenges due to stiff competition and economic uncertainties. However, constant need and demand for medical instruments should continue to drive industry growth, and the segment is anticipated to grow at a CAGR rate of about 6% through 2017, according to Espicom's 2014 report. Stock-Callers.com looks closely at the following stocks today: ZELTIQ Aesthetics Inc. (NASDAQ: ZLTQ), Align Technology Inc. (NASDAQ: ALGN), Nxstage Medical Inc. (NASDAQ: NXTM), and Nevro Corp. (NYSE: NVRO). Sign up today and download for free the research reports for the stocks covered today at:
NXTM: 22.09 (-0.02), ZLTQ: 33.57 (-0.38), ALGN: 89.69 (+0.54), NVRO: 82.34 (-0.36)
Bet on These 5 Profitable Stocks to Boost Your Returns
Zacks Equity Research - Zacks Investment Research - Mon Jul 18, 8:17AM CDT
One of the best tools to measure the future performance of a company's stocks is profitability analysis.
NXTM: 22.09 (-0.02), ALGN: 89.69 (+0.54), AL: 28.58 (-0.23), REI: 7.59 (-0.35), TAHO: 15.70 (+0.14)
Illumina (ILMN) Rallies on Exact Sciences Buyout Rumor
Zacks Equity Research - Zacks Investment Research - Wed Jul 13, 7:53AM CDT
With this buyout, Illumina (ILMN) will gain control over Cologuard -- a FDA approved non-invasive screening test of Exact Sciences that uses stool DNA technology to detect colorectal cancer.
NXTM: 22.09 (-0.02), GWPH: 96.11 (+1.79), TGTX: 5.79 (-0.12), ILMN: 170.65 (+4.30)
Boston Scientific's Restructuring Plan & Innovation Offer Hope
Zacks Equity Research - Zacks Investment Research - Wed Jul 13, 7:30AM CDT
On Jul 13, 2016, we issued an updated research report on Boston Scientific Corporation (BSX).
BSX: 24.43 (+0.15), NXTM: 22.09 (-0.02), GWPH: 96.11 (+1.79), NUVA: 63.29 (+1.09)
FDA Okays Medtronic's NuVent for Expanded Use in Sinusitis
Zacks Equity Research - Zacks Investment Research - Tue Jul 12, 7:17PM CDT
Medtronic's (MDT) NuVent is a unique balloon sinus dilation system, which enables a better view of one's sinus anatomy and the optimal placement of balloons during surgery.
NXTM: 22.09 (-0.02), MDT: 88.06 (+0.43), GWPH: 96.11 (+1.79), TGTX: 5.79 (-0.12)
Illumina Stock Hit by Downbeat Guidance, Stiff Competition
Zacks Equity Research - Zacks Investment Research - Fri Jul 08, 9:27AM CDT
Illumina (ILMN) faces high expenses related to the development of new products, their launch in various markets and investments in partnerships
ICUI: 117.07 (+0.31), NXTM: 22.09 (-0.02), GWPH: 96.11 (+1.79), ILMN: 170.65 (+4.30)
Halyard Health Now a Strong Buy, Portfolio Key Catalyst
Zacks Equity Research - Zacks Investment Research - Fri Jul 08, 7:54AM CDT
On Jul 8, 2016, Zacks Investment Research upgraded Halyard Health Inc (HYH) to a Zacks Rank #1 (Strong Buy).
HYH: 34.07 (-0.52), DSCI: 4.74 (-0.03), ICUI: 117.07 (+0.31), NXTM: 22.09 (-0.02)
Why Investors Love These Medical Appliances & Equipment's Stocks? - Align Technology, ZELTIQ Aesthetics, Amedica, and Nxstage Medical
PR Newswire - Wed Jun 22, 6:45AM CDT
Growth is expected for the U.S. Medical Appliances and Equipment industry as demand for healthcare continues to rise. In today's pre-market research, Stock-Callers.com shifts its attention on these four equities for investors' close review: Align Technology Inc. (NASDAQ: ALGN), ZELTIQ Aesthetics Inc. (NASDAQ: ZLTQ), Amedica Corp. (NASDAQ: AMDA), and Nxstage Medical Inc. (NASDAQ: NXTM). Learn more about these stocks and receive your complimentary trade alerts at:
NXTM: 22.09 (-0.02), ZLTQ: 33.57 (-0.38), ALGN: 89.69 (+0.54), AMDA: 0.84 (+0.01)
Uptrend Call Working As NxStage Medical Stock Rises 33.4% (NXTM)
Comtex SmarTrend(R) - Fri Jun 10, 1:01PM CDT
SmarTrend identified an Uptrend for NxStage Medical (NASDAQ:NXTM) on March 7th, 2016 at $15.61. In approximately 3 months, NxStage Medical has returned 33.38% as of today's recent price of $20.82.
NXTM: 22.09 (-0.02)
Nxstage Medical (NXTM) Catches Eye: Stock Jumps 5.6%
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 7:40AM CDT
Nxstage Medical, Inc. (NXTM) saw its shares almost 6% in the last trading session.
NXTM: 22.09 (-0.02), BAX: 48.50 (+0.48)
Uptrend Call Working As NxStage Medical Stock Rises 25.8% (NXTM)
Comtex SmarTrend(R) - Fri Jun 03, 1:20AM CDT
SmarTrend identified an Uptrend for NxStage Medical (NASDAQ:NXTM) on March 7th, 2016 at $15.61. In approximately 3 months, NxStage Medical has returned 25.82% as of today's recent price of $19.64.
NXTM: 22.09 (-0.02)
NxStage Medical Has Returned 19.2% Since SmarTrend Recommendation (NXTM)
Comtex SmarTrend(R) - Thu May 26, 1:52PM CDT
SmarTrend identified an Uptrend for NxStage Medical (NASDAQ:NXTM) on March 7th, 2016 at $15.61. In approximately 3 months, NxStage Medical has returned 19.15% as of today's recent price of $18.60.
NXTM: 22.09 (-0.02)
NxStage Announces Second Quarter 2016 Investor Conference Schedule
PR Newswire - Tue May 24, 7:00AM CDT
NxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company focused on advancing renal care, today announced that Jeffrey H. Burbank, Chief Executive Officer, plans to participate in the following schedule of investor conferences. Where applicable, a webcast of the event will be made available at http://ir.nxstage.com/.
NXTM: 22.09 (-0.02)
NxStage Medical Cuts Its Losses as Critical Care Leads Sales Higher
Dan Caplinger, The Motley Fool - Motley Fool - Wed May 04, 10:44AM CDT
Image source: NxStage Medical. Profitability often eludes small companies seeking to expand their businesses, and for home dialysis specialist NxStage Medical , the challenge of spending money on research and development while also marketing its...
NXTM: 22.09 (-0.02)
NxStage Reports First Quarter Financial Results
PR Newswire - Wed May 04, 7:05AM CDT
NxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company focused on advancing renal care, today reported first quarter financial results above the top end of its guidance.
NXTM: 22.09 (-0.02)
NxStage to Present at the Deutsche Bank 41st Annual Health Care Conference
PR Newswire - Mon Apr 25, 7:00AM CDT
NxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company focused on advancing renal care, today announced that Jeffrey H. Burbank, Chief Executive Officer, plans to present at the Deutsche Bank 41st Annual Health Care Conference on Thursday, May 5, 2016 at 8:40 a.m. ET in Boston, MA. A webcast of the event will be made available at http://ir.nxstage.com/.
NXTM: 22.09 (-0.02)
Zerto Launches the Inaugural ZertoCON: The Next Generation Business Continuity Conference
PR Newswire - Wed Apr 13, 7:30AM CDT
Zerto, setting the standard for protection, recovery and migration of data in cloud and virtualized data centers, today announced the launch of ZertoCON, the next generation business continuity conference, taking place May 23-25, 2016 in Boston, MA. Executives, thought leaders and IT professionals from a wide range of industries and organizations - including Zerto's management and product leaders - will focus on building confidence in IT to move businesses forward.
NXTM: 22.09 (-0.02)
NxStage® to Report First Quarter 2016 Financial Results
PR Newswire - Mon Apr 11, 7:00AM CDT
NxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company focused on advancing renal care, today announced plans to release its financial results for the first quarter ended March 31, 2016, on Wednesday, May 4, 2016, before the opening of the financial markets.
NXTM: 22.09 (-0.02)
National Donate Life Month: NxStage Teams Up with Organ Donation Nonprofit MatchingDonors.com
PR Newswire - Thu Apr 07, 7:00AM CDT
Thirteen people die every day in the United States waiting for a kidney transplant, most waiting seven to nine years, according to the U.S. Department of Health and Human Services. April is National Donate Life Month and NxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company focused on advancing renal care, is joining forces with MatchingDonors.com, the nation's largest nonprofit living organ donation website that provides people with an active way to search for an altruistic live donor. The organizations are teaming up to raise awareness of treatment options and services that may help kidney patients receive a transplant.
NXTM: 22.09 (-0.02)
Why NxStage Medical, Inc. Guided Lower Today
Brian Orelli, The Motley Fool - Motley Fool - Wed Feb 10, 3:48PM CST
What: NxStage Medical is down 14% near the closing bell after releasing disappointing guidance during its fourth-quarter earnings release this morning. So what: Fourth-quarter revenue was pretty strong, up 12% year over year. NxStage Medical...
NXTM: 22.09 (-0.02)
